Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Joy Ho

Showing results (11-20 of 81) with videos related to

Pageof 9
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2016
The T Cell in MyelomaDouglas Joshua, Hayley Suen, Ross Brown, et al.
American Journal of Hematology|January 25, 2006
Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation?Silvia Ling, Douglas E Joshua, John Gibson, et al.
Leukemia & Lymphoma|February 15, 2012
Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trialP Joy Ho, Ross D Brown, Andrew Spencer, et al.
British Journal of Haematology|June 8, 2004
Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myelomaRoss Brown, Allan Murray, Belinda Pope, et al.
Internal Medicine Journal|March 6, 2017
A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosisP Joy Ho, Ashish Bajel, Kate Burbury, et al.
Cancer Chemotherapy and Pharmacology|April 21, 2017
Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I studyHang Quach, Darrell White, Andrew Spencer, et al.
Expert Review of Proteomics|November 7, 2022
The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory diseasePaul G Richardson, María-Victoria Mateos, Annette J Vangsted, et al.
Leukemia & Lymphoma|July 20, 2013
Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive stateJames Favaloro, Ross Brown, Esther Aklilu, et al.
Internal Medicine Journal|April 2, 2025
Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T-cell therapy for relapsed and refractory lymphomaMichael Dickinson, Nicole O'Leary, Nada Hamad, et al.
Blood|June 19, 2012
CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosisRoss Brown, Karieshma Kabani, James Favaloro, et al.
Pageof 9

Showing results (11-20 of 81) with videos related to

Sort By:
Pageof 9
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2016
The T Cell in MyelomaDouglas Joshua, Hayley Suen, Ross Brown, et al.
American Journal of Hematology|January 25, 2006
Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation?Silvia Ling, Douglas E Joshua, John Gibson, et al.
Leukemia & Lymphoma|February 15, 2012
Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trialP Joy Ho, Ross D Brown, Andrew Spencer, et al.
British Journal of Haematology|June 8, 2004
Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myelomaRoss Brown, Allan Murray, Belinda Pope, et al.
Internal Medicine Journal|March 6, 2017
A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosisP Joy Ho, Ashish Bajel, Kate Burbury, et al.
Cancer Chemotherapy and Pharmacology|April 21, 2017
Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I studyHang Quach, Darrell White, Andrew Spencer, et al.
Expert Review of Proteomics|November 7, 2022
The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory diseasePaul G Richardson, María-Victoria Mateos, Annette J Vangsted, et al.
Leukemia & Lymphoma|July 20, 2013
Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive stateJames Favaloro, Ross Brown, Esther Aklilu, et al.
Internal Medicine Journal|April 2, 2025
Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T-cell therapy for relapsed and refractory lymphomaMichael Dickinson, Nicole O'Leary, Nada Hamad, et al.
Blood|June 19, 2012
CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosisRoss Brown, Karieshma Kabani, James Favaloro, et al.
Pageof 9